Anna Alonzo, BS

Articles

September 11th 2023

Implementation of the Accountable Health Communities Model in Arizona

Micaela Mercado, PhD, LMSW Wendy Wolfersteig, PhD Anna Alonzo, BS

The Accountable Health Communities Model facilitates multisector coordination. Implementation science elucidated the contextual factors that facilitated the use of this model in Arizona.

Latest Updated Articles

Published: February 20th 2025 | Updated: February 21st 2025

Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP

Hands holding pack of cigarettes | Image credit: Nopphon – stock.adobe.com

Published: January 16th 2025 | Updated: January 29th 2025

FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Recent Content

Based on the model, over 3 million MACE were projected over the following 10 years, approximately 496,000 of which could be prevented with the use of semaglutide. | Image credit: peter hansen - stock.adobe.com

Semaglutide Use Could Prevent Up to 2 Million MACE in 10 Years, Model Suggests

The MUSETTE trial did not meet its primary end point, suggesting a higher dose of IV ocrelizumab does not provide added benefits compared with the currently approved 600 mg dose. | Image credit: Chanintorn.v - stock.adobe.com

Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

Diabetes concept | Image credit: Sherry Young - stock.adobe.com

GLP-1 RAs, SGLT2 Inhibitors Associated With Reduced MACE, HHF in Patients With Diabetes

Man rubbing his eyes | Image credit: Prostock-studio - stock.adobe.com

Sleep Disruptions Contribute to Likelihood of Dry Eye Syndrome

View More Recent Content

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions